[
  {
    "ts": null,
    "headline": "Pharma Stocks Are Close to Breaking Out. Earnings Could Set Them Free.",
    "summary": "Pharmaceutical stocks just broke out to new highs—and earnings could push them even higher.  The  exchange-traded fund is up 32% in the past six months to almost $57.  Also helping the rally is that healthcare companies are investing in artificial intelligence to help them identify revenue opportunities with lower costs, potentially lifting profit margins.",
    "url": "https://finnhub.io/api/news?id=d680fcc926368f93c29c79205fee63d7f68d21e64787987f131581084144d6b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769622420,
      "headline": "Pharma Stocks Are Close to Breaking Out. Earnings Could Set Them Free.",
      "id": 138287497,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Pharmaceutical stocks just broke out to new highs—and earnings could push them even higher.  The  exchange-traded fund is up 32% in the past six months to almost $57.  Also helping the rally is that healthcare companies are investing in artificial intelligence to help them identify revenue opportunities with lower costs, potentially lifting profit margins.",
      "url": "https://finnhub.io/api/news?id=d680fcc926368f93c29c79205fee63d7f68d21e64787987f131581084144d6b6"
    }
  },
  {
    "ts": null,
    "headline": "Some of Pharma's Biggest Brands Face a New Reality",
    "summary": "A government process quietly moves forward",
    "url": "https://finnhub.io/api/news?id=48ae2d909b1bce31a2977fa3cc46c5767b5b75f264a8467010fbce54b699fc3f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769611689,
      "headline": "Some of Pharma's Biggest Brands Face a New Reality",
      "id": 138281443,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "A government process quietly moves forward",
      "url": "https://finnhub.io/api/news?id=48ae2d909b1bce31a2977fa3cc46c5767b5b75f264a8467010fbce54b699fc3f"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=2a19867c471563ce83875f6931aaa2e750eb7b186f68249727b6db7ab95d0d48",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769608804,
      "headline": "Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know",
      "id": 138281565,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=2a19867c471563ce83875f6931aaa2e750eb7b186f68249727b6db7ab95d0d48"
    }
  },
  {
    "ts": null,
    "headline": "Gilead price target raised to $145 from $140 at Truist",
    "summary": "Truist raised the firm’s price target on Gilead (GILD) to $145 from $140 and keeps a Buy rating on the shares as part of a broader research note previewing Q4 earnings in Biotech. The firm is adjusting Yeztugo numbers heading into Q4 EPS, tweaking its timelines based on updated guidance for near-term launches, including BIC/LEN in 2H25, US launch of Hepcludex, and expansion opportunity for Livdelzi, and also fine-tuning its estimates for the anito-cel launch following FDA guidance, the analyst t",
    "url": "https://finnhub.io/api/news?id=8ef1a9613cd5d0799290aae1ef7bc25a1d5c8fd97c2f573c90a58d1787bdd3a7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769606426,
      "headline": "Gilead price target raised to $145 from $140 at Truist",
      "id": 138280696,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Truist raised the firm’s price target on Gilead (GILD) to $145 from $140 and keeps a Buy rating on the shares as part of a broader research note previewing Q4 earnings in Biotech. The firm is adjusting Yeztugo numbers heading into Q4 EPS, tweaking its timelines based on updated guidance for near-term launches, including BIC/LEN in 2H25, US launch of Hepcludex, and expansion opportunity for Livdelzi, and also fine-tuning its estimates for the anito-cel launch following FDA guidance, the analyst t",
      "url": "https://finnhub.io/api/news?id=8ef1a9613cd5d0799290aae1ef7bc25a1d5c8fd97c2f573c90a58d1787bdd3a7"
    }
  },
  {
    "ts": null,
    "headline": "CMS selects next batch of 15 high-cost medicines for third negotiation cycle",
    "summary": "The 15 drugs accounted for $27bn in spending via Medicare Part B and Part D between November 2024 and October 2025.",
    "url": "https://finnhub.io/api/news?id=1934eea251c629d11b9eedf631f389a3683800a20c7fd83d6320c306aa3c8579",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769604538,
      "headline": "CMS selects next batch of 15 high-cost medicines for third negotiation cycle",
      "id": 138280575,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The 15 drugs accounted for $27bn in spending via Medicare Part B and Part D between November 2024 and October 2025.",
      "url": "https://finnhub.io/api/news?id=1934eea251c629d11b9eedf631f389a3683800a20c7fd83d6320c306aa3c8579"
    }
  },
  {
    "ts": null,
    "headline": "Healthy Returns: Botox, Trulicity among 15 drugs added to Medicare price negotiations",
    "summary": "The Trump administration kicked off another round of Medicare drug price negotiations, while Kaiser Permanente agrees to pay a historic settlement.",
    "url": "https://finnhub.io/api/news?id=5ae77557973ed9453fe5371e6a9ab2b8b579680df212327413d4e8b25d81b98e",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769602052,
      "headline": "Healthy Returns: Botox, Trulicity among 15 drugs added to Medicare price negotiations",
      "id": 138282758,
      "image": "https://image.cnbcfm.com/api/v1/image/107188275-16753645842023-02-02t183236z_737430976_rc253z9n9jw3_rtrmadp_0_lilly-results.jpeg?v=1694350801&w=1920&h=1080",
      "related": "GILD",
      "source": "CNBC",
      "summary": "The Trump administration kicked off another round of Medicare drug price negotiations, while Kaiser Permanente agrees to pay a historic settlement. ",
      "url": "https://finnhub.io/api/news?id=5ae77557973ed9453fe5371e6a9ab2b8b579680df212327413d4e8b25d81b98e"
    }
  }
]